{
  "items": "32",
  "sentiment_score_definition": "x <= -0.35: Bearish; -0.35 < x <= -0.15: Somewhat-Bearish; -0.15 < x < 0.15: Neutral; 0.15 <= x < 0.35: Somewhat_Bullish; x >= 0.35: Bullish",
  "relevance_score_definition": "0 < x <= 1, with a higher score indicating higher relevance.",
  "feed": [
    {
      "title": "Analysts Offer Insights on Healthcare Companies: Novan (NOVN) and OmniAb (OABI)",
      "url": "https://www.theglobeandmail.com/investing/markets/stocks/NOVN/pressreleases/36647255/analysts-offer-insights-on-healthcare-companies-novan-novn-and-omniab-oabi/",
      "time_published": "20251216T140903",
      "authors": [
        "Tipranks"
      ],
      "summary": "Two analysts have issued bullish sentiments on healthcare companies Novan (NOVN) and OmniAb (OABI). While the article mentions Novan, it only provides details for OmniAb, where analyst Matt Hewitt from Craig-Hallum maintained a Buy rating, noting a consensus of Strong Buy with a $6.75 price target.",
      "banner_image": "NULL",
      "source": "The Globe and Mail",
      "category_within_source": "General",
      "source_domain": "The Globe and Mail",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.900405"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.842166"
        }
      ],
      "overall_sentiment_score": 0.444507,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "OABI",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.417254",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Launch of OmniUltra Expands OmniAb\u2019s Reach into New Markets and Applications, Advances Leadership in Antibody Discovery Technologies",
      "url": "https://www.businesswire.com/news/home/20251215018419/en/Launch-of-OmniUltra-Expands-OmniAbs-Reach-into-New-Markets-and-Applications-Advances-Leadership-in-Antibody-Discovery-Technologies",
      "time_published": "20251216T110938",
      "authors": [
        "NULL"
      ],
      "summary": "OmniAb, Inc. (NASDAQ: OABI) has launched its new OmniUltra\u2122 platform, the first transgenic chicken engineered to express ultralong CDRH3 domains on a human antibody framework, at the 2025 Antibody Engineering & Therapeutics Conference. This innovative platform broadens therapeutic opportunities beyond conventional antibodies and introduces picobodies\u2122, the smallest known natural antibody-derived binding domain. OmniUltra is designed to deliver pre-optimized specificity, affinity, and structural stability for various applications, reinforcing OmniAb's leadership in drug discovery innovation.",
      "banner_image": "https://mms.businesswire.com/media/20251215018419/en/2670780/4/5780918cOmniUltra_Image_Blue.jpg?download=1",
      "source": "Business Wire",
      "category_within_source": "General",
      "source_domain": "Business Wire",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.924331"
        },
        {
          "topic": "finance",
          "relevance_score": "0.627510"
        }
      ],
      "overall_sentiment_score": 0.844289,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "OABI",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.836594",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Launch of OmniUltra Expands OmniAb\u2019s Reach into New Markets and Applications, Advances Leadership in Antibody Discovery Technologies",
      "url": "https://www.biospace.com/press-releases/launch-of-omniultra-expands-omniabs-reach-into-new-markets-and-applications-advances-leadership-in-antibody-discovery-technologies",
      "time_published": "20251216T090910",
      "authors": [],
      "summary": "OmniAb, Inc. has launched its new OmniUltra\u2122 platform, the industry's first transgenic chicken engineered to express ultralong CDRH3 domains on a human antibody framework. This platform broadens therapeutic opportunities beyond conventional antibodies, enabling the discovery of novel binding modes and access to challenging targets, and facilitating applications in areas like bispecifics, multispecifics, CAR-T, and stand-alone peptide therapeutics. OmniUltra also allows for the isolation of picobodies\u2122, the smallest natural antibody-derived binding domains, and represents a pioneering advancement in antibody and peptide discovery.",
      "banner_image": "https://mms.businesswire.com/media/20251215018419/en/2670780/22/5780918cOmniUltra_Image_Blue.jpg",
      "source": "BioSpace",
      "category_within_source": "General",
      "source_domain": "BioSpace",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.937312"
        },
        {
          "topic": "technology",
          "relevance_score": "0.745696"
        },
        {
          "topic": "finance",
          "relevance_score": "0.641197"
        }
      ],
      "overall_sentiment_score": 0.481059,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "OABI",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.460464",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "OmniAb Insiders Enjoying US$277k Appreciation On US$1.59m Investment",
      "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-oabi/omniab/news/omniab-insiders-enjoying-us277k-appreciation-on-us159m-inves",
      "time_published": "20251214T120910",
      "authors": [
        "Simply Wall St"
      ],
      "summary": "OmniAb (NASDAQ: OABI) insiders who invested US$1.59 million in the last year have seen their holdings appreciate by US$277,000, thanks to a 10% stock gain. This included a significant US$1 million purchase by President Matthew Foehr at a price below the current market value, suggesting insiders see value in the company. Overall, insiders bought more shares than they sold, and their collective ownership stands at 12%, aligning their interests with other shareholders.",
      "banner_image": "https://images.simplywall.st/news/images/blue-bear.svg",
      "source": "Simply Wall Street",
      "category_within_source": "General",
      "source_domain": "Simply Wall Street",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.915003"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.703817"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.629368"
        },
        {
          "topic": "technology",
          "relevance_score": "0.628602"
        }
      ],
      "overall_sentiment_score": 0.40842,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "OABI",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.443301",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "OmniAb Insiders Enjoying US$277k Appreciation On US$1.59m Investment",
      "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-oabi/omniab/news/omniab-insiders-enjoying-us277k-appreciation-on-us159m-inves/amp",
      "time_published": "20251213T130905",
      "authors": [
        "Simply Wall St"
      ],
      "summary": "Insiders at OmniAb, Inc. have seen a significant appreciation of US$277k on their US$1.59m investment over the last 12 months, largely due to a 10% stock gain. While individual transactions vary, there has been more insider buying than selling, indicating confidence in the company, despite it currently incurring losses. Insiders own 12% of the company, suggesting good alignment with shareholders.",
      "banner_image": null,
      "source": "Simply Wall Street",
      "category_within_source": "General",
      "source_domain": "Simply Wall Street",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "0.867062"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.945361"
        }
      ],
      "overall_sentiment_score": 0.473737,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "OABI",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.489776",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "OmniAb Insiders Enjoying US$277k Appreciation On US$1.59m Investment",
      "url": "https://www.sahmcapital.com/news/content/omniab-insiders-enjoying-us277k-appreciation-on-us159m-investment-2025-12-13",
      "time_published": "20251213T110938",
      "authors": [
        "Simply Wall St"
      ],
      "summary": "Insiders at OmniAb, Inc. (NASDAQ:OABI) have seen a US$277k appreciation on their US$1.59m investment over the last year, coinciding with a 10% increase in the company's market value. While one significant purchase was made below the current price, overall insider buying exceeded selling, indicating confidence in the company's future despite current losses. Insiders collectively own 12% of OmniAb, aligning their interests with other shareholders.",
      "banner_image": "https://images.simplywall.st/asset/chart/1765536061-insider-trading-volume-1-dark-2/1765631228415",
      "source": "Sahm",
      "category_within_source": "General",
      "source_domain": "Sahm",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "0.812841"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.735281"
        }
      ],
      "overall_sentiment_score": 0.476014,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "OABI",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.451950",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "OmniAb unveils OmniUltra chickens at antibody conference",
      "url": "https://tradersunion.com/news/market-voices/show/1065999-omniab-omniultra-chickens/",
      "time_published": "20251211T170953",
      "authors": [
        "Iryna Sazhynska"
      ],
      "summary": "OmniAb debuted its new OmniUltra platform at the Antibody Engineering & Therapeutics conference, showcasing transgenic chickens that produce ultralong CDRH3 antibodies. This innovative technology promises broad epitope coverage and enhanced precision for targeting conserved mammalian proteins, potentially revolutionizing therapeutic approaches. The development builds upon OmniAb's strategic partnerships and commitment to advancing antibody discovery platforms.",
      "banner_image": "https://files.tradersunion.com/images/twitter-news/omniabtech/omniabtech_01.jpg",
      "source": "Traders Union",
      "category_within_source": "General",
      "source_domain": "Traders Union",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.900625"
        }
      ],
      "overall_sentiment_score": 0.515414,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "OABI",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.500767",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Foehr, OmniAb CEO, sells $27k in shares",
      "url": "https://www.investing.com/news/insider-trading-news/foehr-omniab-ceo-sells-27k-in-shares-93CH-4398760",
      "time_published": "20251211T100949",
      "authors": [
        "Investing.com"
      ],
      "summary": "OmniAb, Inc. President and CEO Matthew W. Foehr recently sold 13,666 shares of common stock for approximately $26,785, following the exercise of options to acquire additional shares. Despite a decrease in Q3 revenue and a net loss, the company's shares have shown significant momentum with recent gains, and analysts project potential upside from current levels. OmniAb maintains a strong financial position, holding more cash than debt and a robust current ratio, even though it is not yet profitable.",
      "banner_image": "https://i-invdn-com.investing.com/news/news_headline_rolled_69x52._800x533_L_1419494221.jpg",
      "source": "Investing.com",
      "category_within_source": "General",
      "source_domain": "Investing.com",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.936659"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.803531"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.735406"
        }
      ],
      "overall_sentiment_score": 0.021022,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "OABI",
          "relevance_score": "0.306018",
          "ticker_sentiment_score": "0.020866",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "OmniAb (NASDAQ:OABI) CEO Sells $26,785.36 in Stock",
      "url": "https://www.marketbeat.com/instant-alerts/omniab-nasdaqoabi-ceo-sells-2678536-in-stock-2025-12-09/",
      "time_published": "20251210T130949",
      "authors": [
        "MarketBeat"
      ],
      "summary": "OmniAb, Inc.'s (NASDAQ:OABI) CEO, Matthew Foehr, sold 13,666 shares of the company's stock on December 8th for a total of $26,785.36, decreasing his stake by 0.31%. Despite the sale, OmniAb's stock currently holds a \"Moderate Buy\" consensus rating from analysts, with a target price of $6.67, though Weiss Ratings reiterated a \"sell\" rating. The company recently reported quarterly EPS of ($0.14), beating estimates by $0.01, but missed revenue expectations.",
      "banner_image": "https://www.marketbeat.com/logos/omniab-inc-logo-1200x675.png?v=20221202154239",
      "source": "MarketBeat",
      "category_within_source": "General",
      "source_domain": "MarketBeat",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.922287"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.811436"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.717094"
        }
      ],
      "overall_sentiment_score": -0.246316,
      "overall_sentiment_label": "Somewhat-Bearish",
      "ticker_sentiment": [
        {
          "ticker": "OABI",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.235146",
          "ticker_sentiment_label": "Somewhat-Bearish"
        }
      ]
    },
    {
      "title": "OmniAb CFO Gustafson sells $46,887 in shares",
      "url": "https://www.investing.com/news/insider-trading-news/omniab-cfo-gustafson-sells-46887-in-shares-93CH-4398797",
      "time_published": "20251210T130949",
      "authors": [
        "Investing.com"
      ],
      "summary": "OmniAb's CFO, Kurt A. Gustafson, sold 23,922 shares of common stock worth $46,887 to cover tax obligations related to restricted stock unit vesting. This transaction occurred after a week where OmniAb shares gained 16.37%, with the company maintaining a strong financial position despite a recent decline in revenue reported in Q3. Analyst targets for OmniAb shares range from $3 to $11.",
      "banner_image": "https://i-invdn-com.investing.com/news/international_newspapers_69x52._800x533_L_1419494241.jpg",
      "source": "Investing.com",
      "category_within_source": "General",
      "source_domain": "Investing.com",
      "topics": [
        {
          "topic": "financial_markets",
          "relevance_score": "0.901055"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.839637"
        },
        {
          "topic": "finance",
          "relevance_score": "0.721287"
        }
      ],
      "overall_sentiment_score": 0.130021,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "OABI",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.116656",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Here's Why We're Not Too Worried About OmniAb's (NASDAQ:OABI) Cash Burn Situation",
      "url": "https://finance.yahoo.com/news/heres-why-were-not-too-114327414.html",
      "time_published": "20251210T120926",
      "authors": [
        "Simply Wall St"
      ],
      "summary": "OmniAb (NASDAQ:OABI) has a cash runway of about 20 months, having burnt through US$35m in the last year against US$60m in cash reserves. Analysts project the company will hit cashflow breakeven in around 22 months, suggesting they may not need to raise additional capital. Despite flat revenue over the past year, a 25% reduction in cash burn and a manageable cash burn relative to market capitalization ($35m burn vs $286m market cap) contribute to a positive outlook regarding its financial health.",
      "banner_image": "https://s.yimg.com/ny/api/res/1.2/HkW.of1x4JHpvrHVFxKcTA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwODtoPTQ4O2NmPXdlYnA-/https://s.yimg.com/os/creatr-uploaded-images/2021-03/7d6207c0-7d34-11eb-bbee-858baefb8682",
      "source": "Yahoo Finance",
      "category_within_source": "General",
      "source_domain": "Yahoo Finance",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.944837"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.806262"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.700145"
        }
      ],
      "overall_sentiment_score": 0.343261,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "OABI",
          "relevance_score": "0.981613",
          "ticker_sentiment_score": "0.311848",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "OmniAb CFO Gustafson sells $46,887 in shares By Investing.com",
      "url": "https://za.investing.com/news/insider-trading-news/omniab-cfo-gustafson-sells-46887-in-shares-93CH-4020085",
      "time_published": "20251209T170926",
      "authors": [
        "NULL"
      ],
      "summary": "OmniAb's CFO, Kurt A. Gustafson, sold 23,922 shares of common stock for $46,887 to cover tax obligations related to restricted stock units (RSUs). This transaction occurred after OmniAb shares saw a significant gain, with Gustafson also acquiring 46,500 shares through RSU vesting. Despite a recent revenue decrease, investor sentiment appears optimistic, evidenced by an aftermarket stock price rise.",
      "banner_image": "https://i-invdn-com.investing.com/news/international_newspapers_69x52._800x533_L_1419494241.jpg",
      "source": "Investing.com South Africa",
      "category_within_source": "General",
      "source_domain": "Investing.com South Africa",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.915215"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.828825"
        },
        {
          "topic": "finance",
          "relevance_score": "0.707791"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.612909"
        }
      ],
      "overall_sentiment_score": 0.064007,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "OABI",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.080764",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "OmniAb (OABI) chief legal officer Berkman sells $15,766 in stock By Investing.com",
      "url": "https://za.investing.com/news/insider-trading-news/omniab-oabi-chief-legal-officer-berkman-sells-15766-in-stock-93CH-4020070",
      "time_published": "20251209T161200",
      "authors": [
        "Investing.com"
      ],
      "summary": "OmniAb's Chief Legal Officer, Charles S. Berkman, sold 8,044 shares of common stock for approximately $15,766 to cover tax withholding obligations after the vesting of restricted stock units. Despite this transaction, which was not a discretionary trade, OmniAb's stock has shown significant recent momentum. The company reported a decline in Q3 revenue and a net loss, but its strategic plans have maintained investor confidence, with its stock trading near its Fair Value estimate.",
      "banner_image": "https://i-invdn-com.investing.com/news/World_News_9_800x533_L_1420026261.jpg",
      "source": "Investing.com South Africa",
      "category_within_source": "General",
      "source_domain": "Investing.com South Africa",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.934520"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.707519"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.636265"
        },
        {
          "topic": "finance",
          "relevance_score": "0.644311"
        }
      ],
      "overall_sentiment_score": -0.183707,
      "overall_sentiment_label": "Somewhat-Bearish",
      "ticker_sentiment": [
        {
          "ticker": "OABI",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.219982",
          "ticker_sentiment_label": "Somewhat-Bearish"
        }
      ]
    },
    {
      "title": "OmniAb (NASDAQ:OABI) Insider Charles Berkman Sells 8,044 Shares",
      "url": "https://www.marketbeat.com/instant-alerts/omniab-nasdaqoabi-insider-charles-berkman-sells-8044-shares-2025-12-09/",
      "time_published": "20251209T140927",
      "authors": [
        "MarketBeat"
      ],
      "summary": "OmniAb (NASDAQ:OABI) insider Charles Berkman sold 8,044 shares of the company's stock on December 8th at an average price of $1.96, totaling $15,766.24. This transaction reduced his stake by 2.09% to 377,071 shares. Despite the insider sale and recent revenue miss, analysts maintain a \"Moderate Buy\" consensus rating with a $6.67 price target, while Weiss Ratings reissued a \"sell (d-)\" rating.",
      "banner_image": "https://www.marketbeat.com/logos/omniab-inc-logo-1200x675.png?v=20221202154239",
      "source": "MarketBeat",
      "category_within_source": "General",
      "source_domain": "MarketBeat",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.903168"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.833674"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.731978"
        }
      ],
      "overall_sentiment_score": 0.021489,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "OABI",
          "relevance_score": "0.316504",
          "ticker_sentiment_score": "0.022558",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "OmniAb Executives Sell Shares to Cover Tax Obligations",
      "url": "https://www.tradingview.com/news/tradingview:c7dbfef5f61a6:0-omniab-executives-sell-shares-to-cover-tax-obligations/",
      "time_published": "20251209T140927",
      "authors": [],
      "summary": "Several OmniAb executives, including CEO Matthew W. Foehr, Chief Legal Officer Charles S. Berkman, and Executive VP of Finance Kurt A. Gustafson, recently sold company shares. These sales were made to cover tax withholding obligations associated with the vesting of Restricted Stock Units (RSUs) at a weighted average price of $1.96 per share. The transactions involved significant amounts, with Foehr selling 13,666 shares, Berkman selling 8,044 shares, and Gustafson selling 23,922 shares.",
      "banner_image": "https://s3-symbol-logo.tradingview.com/omniab.svg",
      "source": "TradingView",
      "category_within_source": "General",
      "source_domain": "TradingView",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "0.942433"
        },
        {
          "topic": "economy_fiscal",
          "relevance_score": "0.703707"
        }
      ],
      "overall_sentiment_score": 0.005228,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "OABI",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.032918",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "OmniAb (NASDAQ:OABI) CFO Sells $46,887.12 in Stock",
      "url": "https://www.marketbeat.com/instant-alerts/omniab-nasdaqoabi-cfo-sells-4688712-in-stock-2025-12-09/",
      "time_published": "20251209T140926",
      "authors": [
        "MarketBeat"
      ],
      "summary": "OmniAb's CFO, Kurt Gustafson, sold 23,922 shares of the company's stock for $46,887.12 on December 8th, reducing his stake by 8.65%. The biotech company, trading near $1.99, has a market cap of $286.5 million and reported a loss of $0.14 EPS last quarter, missing revenue estimates. Despite institutional ownership of 72.08% and a \"Moderate Buy\" consensus rating from analysts, Weiss Ratings reiterated a \"sell (D-)\" opinion.",
      "banner_image": "https://www.marketbeat.com/logos/omniab-inc-logo-1200x675.png?v=20221202154239",
      "source": "MarketBeat",
      "category_within_source": "General",
      "source_domain": "MarketBeat",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.915011"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.802361"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.701016"
        },
        {
          "topic": "finance",
          "relevance_score": "0.647141"
        }
      ],
      "overall_sentiment_score": -0.213581,
      "overall_sentiment_label": "Somewhat-Bearish",
      "ticker_sentiment": [
        {
          "ticker": "OABI",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.232125",
          "ticker_sentiment_label": "Somewhat-Bearish"
        }
      ]
    },
    {
      "title": "OmniAb to Hold OmniUltra Virtual Investor Event on December 15",
      "url": "https://finance.yahoo.com/news/omniab-hold-omniultra-virtual-investor-210500861.html",
      "time_published": "20251205T140924",
      "authors": [
        "NULL"
      ],
      "summary": "OmniAb, Inc. (NASDAQ: OABI) announced it will host a virtual investor event on December 15, 2025, at 5:00 p.m. Eastern time to launch OmniUltra. This event will introduce OmniAb's newest technology, OmniUltra, which is a transgenic chicken engineered to express ultralong CDRH3 domains on a human antibody framework, highlighting its market applications and strategic importance. The event will include a review of the technology, its applications, and its strategic importance to the business.",
      "banner_image": "https://s.yimg.com/ny/api/res/1.2/dHE396X1M1w0Zv1ePeyEmw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIzNjtoPTQ4O2NmPXdlYnA-/https://s.yimg.com/os/creatr-uploaded-images/2020-11/29c0c440-2a63-11eb-aff7-af8d7ebd46a4",
      "source": "Yahoo Finance",
      "category_within_source": "General",
      "source_domain": "Yahoo Finance",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.907985"
        }
      ],
      "overall_sentiment_score": 0.429471,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "OABI",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.448356",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "OmniAb to Hold OmniUltra Virtual Investor Event on December 15",
      "url": "https://www.businesswire.com/news/home/20251204562934/en/OmniAb-to-Hold-OmniUltra-Virtual-Investor-Event-on-December-15",
      "time_published": "20251205T043243",
      "authors": [],
      "summary": "OmniAb, Inc. (NASDAQ: OABI) announced it will host a virtual investor event on December 15, 2025, at 5:00 p.m. Eastern time to launch its new OmniUltra\u2122 technology. OmniUltra is a transgenic chicken engineered to express ultralong CDRH3 domains on a human antibody framework, and the event will detail its market applications and strategic importance.",
      "banner_image": "https://mms.businesswire.com/media/20251204562934/en/2545783/4/OmniAB.jpg",
      "source": "Business Wire",
      "category_within_source": "General",
      "source_domain": "Business Wire",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.932725"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.825091"
        },
        {
          "topic": "finance",
          "relevance_score": "0.636822"
        }
      ],
      "overall_sentiment_score": 0.410329,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "OABI",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.447802",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "OmniAb Enters into a Technology License and Services Agreement for Antibody Discovery with a Newly-Formed Incubated Company of ArrowMark Partners and Viking Global Investors",
      "url": "https://www.businesswire.com/news/home/20251117801230/en/OmniAb-Enters-into-a-Technology-License-and-Services-Agreement-for-Antibody-Discovery-with-a-Newly-Formed-Incubated-Company-of-ArrowMark-Partners-and-Viking-Global-Investors",
      "time_published": "20251117T043243",
      "authors": [],
      "summary": "OmniAb, Inc. has signed a license and services agreement with Mabtrx Biosciences, a joint venture formed by ArrowMark Partners and Viking Global Investors, for novel OmniAb-derived antibody discovery programs. This agreement will generate revenue for OmniAb through discovery services, potential equity, and royalties. The partnership highlights OmniAb's strategy to leverage its transgenic chicken-based technologies for value creation in biotech.",
      "banner_image": "https://mms.businesswire.com/media/20251117801230/en/2545783/4/OmniAB.jpg",
      "source": "Business Wire",
      "category_within_source": "General",
      "source_domain": "Business Wire",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.906763"
        }
      ],
      "overall_sentiment_score": 0.406442,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "OABI",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.406721",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "OmniAb, Inc. (OABI) Expected to Beat Earnings Estimates: Should You Buy?",
      "url": "https://finance.yahoo.com/news/omniab-inc-oabi-expected-beat-140023648.html",
      "time_published": "20251115T120942",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "OmniAb, Inc. (OABI) is expected to show a year-over-year increase in earnings and revenues for the quarter ending September 2025, with results anticipated around November 4. The company's Most Accurate Estimate is higher than the Zacks Consensus Estimate, and with a Zacks Rank of #2, OmniAb, Inc. is highly likely to beat consensus EPS estimates. Investors are advised to consider other factors alongside the positive Earnings ESP and strong Zacks Rank.",
      "banner_image": "https://s.yimg.com/ny/api/res/1.2/zf_1wpp4e4lihErpE5wvzA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyNjtoPTQ4O2NmPXdlYnA-/https://s.yimg.com/os/creatr-uploaded-images/2020-11/3bc15d30-250e-11eb-bffb-472fe5eb11fe",
      "source": "Yahoo Finance",
      "category_within_source": "General",
      "source_domain": "Yahoo Finance",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.948332"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.709054"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.639980"
        }
      ],
      "overall_sentiment_score": 0.453323,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "OABI",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.457522",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "OmniAb director Higgins buys shares worth $107,706",
      "url": "https://www.investing.com/news/insider-trading-news/omniab-director-higgins-buys-shares-worth-107706-93CH-4346108",
      "time_published": "20251110T083800",
      "authors": [
        "Investing.com"
      ],
      "summary": "John L. Higgins, a director at OmniAb, Inc. (NASDAQ:OABI), recently purchased 77,261 shares of the company's common stock for a total of $107,706. These transactions occurred on November 6 and 7, 2025, with shares bought at prices ranging from $1.33 to $1.45, near the stock's 52-week low, following a nearly 70% decline over the past year. Despite the insider buying and the stock being considered undervalued by InvestingPro, the company expects to report earnings soon and analysts have not changed their ratings.",
      "banner_image": "https://i-invdn-com.investing.com/news/news_headline_rolled_69x52._800x533_L_1419494221.jpg",
      "source": "Investing.com",
      "category_within_source": "General",
      "source_domain": "Investing.com",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.836976"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.935111"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.714686"
        }
      ],
      "overall_sentiment_score": 0.139387,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "OABI",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.143461",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "OmniAb, Inc. (NASDAQ:OABI) Q3 2025 Earnings Call Transcript",
      "url": "https://www.insidermonkey.com/blog/omniab-inc-nasdaqoabi-q3-2025-earnings-call-transcript-1641002/",
      "time_published": "20251108T043243",
      "authors": [
        "NULL"
      ],
      "summary": "OmniAb, Inc. reported its Q3 2025 financial results, with revenue of $2.2 million and a net loss of $16.5 million. The company announced the upcoming launch of OmniUltra, a new transgenic chicken platform for antibody and peptide therapeutic discovery, and provided updates on its xPloration partner access program and clinical pipeline advancements. Financial guidance for 2025 was updated, with expected revenue between $18 million and $22 million and operating expenses between $82 million and $86 million.",
      "banner_image": "https://imonkey-blog.imgix.net/blog/wp-content/uploads/2023/10/18213125/OABI-insidermonkey-1697679082947.jpg?auto=format&fit=clip&expires=1796601600&width=480&height=269",
      "source": "Insider Monkey",
      "category_within_source": "General",
      "source_domain": "Insider Monkey",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.921283"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.819072"
        },
        {
          "topic": "finance",
          "relevance_score": "0.728525"
        }
      ],
      "overall_sentiment_score": 0.395379,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "OABI",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.390973",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Leerink Partnrs Issues Positive Estimate for OmniAb Earnings - Defense World",
      "url": "https://www.defenseworld.net/2025/10/17/leerink-partnrs-issues-positive-estimate-for-omniab-earnings.html",
      "time_published": "20251017T153721",
      "authors": [
        "Defense World Staff"
      ],
      "summary": "Leerink Partners has issued a positive forecast for OmniAb, Inc.'s earnings, anticipating $0.05 EPS for the current fiscal quarter. Other institutional investors have also significantly adjusted their holdings in OmniAb, with several increasing their positions. The company, a biotechnology firm, specializes in therapeutic antibody discovery technologies.",
      "banner_image": "https://www.marketbeat.com/logos/omniab-inc-logo-1200x675.png?v=20221202154239",
      "source": "Defense World",
      "category_within_source": "General",
      "source_domain": "Defense World",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.927126"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.706073"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.603560"
        },
        {
          "topic": "finance",
          "relevance_score": "0.539577"
        }
      ],
      "overall_sentiment_score": 0.03415,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "OABI",
          "relevance_score": "0.300877",
          "ticker_sentiment_score": "0.007115",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "OmniAb to Participate in Three Investor Conferences in November 2025 - BioSpace",
      "url": "https://www.biospace.com/press-releases/omniab-to-participate-in-three-investor-conferences-in-november-2025",
      "time_published": "20251017T080720",
      "authors": [],
      "summary": "OmniAb, Inc. announced its participation in three investor conferences in November 2025. CEO Matt Foehr and CFO Kurt Gustafson will engage in one-on-one meetings and corporate presentations at events hosted by Truist Securities, Stifel, and Jefferies. These conferences provide OmniAb with opportunities to interact with investors and present its cutting-edge discovery research technology.",
      "banner_image": null,
      "source": "BioSpace",
      "category_within_source": "General",
      "source_domain": "BioSpace",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.907740"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.728373"
        }
      ],
      "overall_sentiment_score": 0.048184,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "OABI",
          "relevance_score": "0.317775",
          "ticker_sentiment_score": "0.027841",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "OmniAb to Participate in Three Investor Conferences in November - Yahoo Finance",
      "url": "https://finance.yahoo.com/news/omniab-participate-three-investor-conferences-120000855.html",
      "time_published": "20251016T120000",
      "authors": [],
      "summary": "OmniAb, Inc. (NASDAQ: OABI) announced its participation in three investor conferences in November 2025. CEO Matt Foehr and CFO Kurt Gustafson will engage in one-on-one meetings and corporate presentations at the Truist Securities BioPharma Symposium, Stifel 2025 Healthcare Conference, and Jefferies Global Healthcare Conference in London. The company will highlight its antibody discovery research technology.",
      "banner_image": "https://finance.yahoo.com/news/omniab-participate-three-investor-conferences-120000855.html",
      "source": "Yahoo Finance",
      "category_within_source": "General",
      "source_domain": "Yahoo Finance",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.936060"
        }
      ],
      "overall_sentiment_score": 0.000304,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "OABI",
          "relevance_score": "0.310132",
          "ticker_sentiment_score": "0.009440",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "OmniAb to Participate in Three Investor Conferences in November - FinancialContent",
      "url": "https://www.wral.com/wral/article/bizwire-2025-10-16-omniab-to-participate-in-three-investor-conferences-in-november/",
      "time_published": "20251016T120000",
      "authors": [],
      "summary": "OmniAb, Inc. (NASDAQ: OBNT) announced it will participate in three investor conferences in November, including the Stifel Healthcare Conference, Jefferies London Healthcare Conference, and Evercore ISI HealthCONx Conference. Management will engage in one-on-one meetings and present at these events, which will be accessible via webcast.",
      "banner_image": null,
      "source": "FinancialContent",
      "category_within_source": "General",
      "source_domain": "FinancialContent",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.924015"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.728110"
        },
        {
          "topic": "finance",
          "relevance_score": "0.514343"
        }
      ],
      "overall_sentiment_score": 0.012177,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "OABI",
          "relevance_score": "0.326036",
          "ticker_sentiment_score": "0.047408",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "OmniAb (NASDAQ:OABI) Receives Sell (E+) Rating from Weiss Ratings - Defense World",
      "url": "https://www.defenseworld.net/2025/10/15/omniab-nasdaqoabi-receives-sell-e-rating-from-weiss-ratings.html",
      "time_published": "20251015T065923",
      "authors": [
        "Defense World Staff"
      ],
      "summary": "OmniAb (NASDAQ:OABI) has received a Sell (E+) rating from Weiss Ratings. Royal Bank of Canada also lowered its target price for OmniAb shares from $4.00 to $3.00, maintaining an \"outperform\" rating. Institutional investors have been active, with several hedge funds buying or boosting stakes in the company.",
      "banner_image": null,
      "source": "Defense World",
      "category_within_source": "General",
      "source_domain": "Defense World",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.912008"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.810423"
        },
        {
          "topic": "finance",
          "relevance_score": "0.724993"
        }
      ],
      "overall_sentiment_score": 0.033928,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "OABI",
          "relevance_score": "0.308264",
          "ticker_sentiment_score": "0.003363",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "OmniAb to Report Third Quarter 2025 Financial Results on November 4 - PharmiWeb.com",
      "url": "https://www.pharmiweb.com/press-release/2025-10-14/omniab-to-report-third-quarter-2025-financial-results-on-november-4",
      "time_published": "20251014T150456",
      "authors": [],
      "summary": "OmniAb, Inc. will report its financial results for the three and nine months ended September 30, 2025, after the U.S. financial markets close on Tuesday, November 4, 2025. The company will also host a conference call on the same day at 4:30 p.m. Eastern time to discuss the results and provide business updates. OmniAb specializes in licensing discovery research technology for next-generation therapeutics, utilizing its Biological Intelligence\u2122 platform for antibody and target-binding protein discovery.",
      "banner_image": null,
      "source": "PharmiWeb.com",
      "category_within_source": "General",
      "source_domain": "PharmiWeb.com",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.933176"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.703182"
        }
      ],
      "overall_sentiment_score": 0.005814,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "OABI",
          "relevance_score": "0.340068",
          "ticker_sentiment_score": "0.018256",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "OmniAb to Participate at the H.C. Wainwright 27th Annual Global Investment Conference",
      "url": "https://www.biospace.com/press-releases/omniab-to-participate-at-the-h-c-wainwright-27th-annual-global-investment-conference",
      "time_published": "20250903T043243",
      "authors": [],
      "summary": "OmniAb, Inc. (NASDAQ: OABI) announced its management will participate in the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025, with one-on-one meetings scheduled for September 9th. The company aims to connect with investors and highlight its cutting-edge discovery research technology, which leverages diverse antibody repertoires and proprietary transgenic animals to identify optimal antibodies for therapeutic development. OmniAb's business model includes upfront fees, service revenue, milestones, and royalties on commercial sales.",
      "banner_image": "https://mms.businesswire.com/media/20250902298314/en/2545783/22/OmniAB.jpg",
      "source": "BioSpace",
      "category_within_source": "General",
      "source_domain": "BioSpace",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.900506"
        },
        {
          "topic": "finance",
          "relevance_score": "0.732125"
        }
      ],
      "overall_sentiment_score": 0.105165,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "OABI",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.148972",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Tourlite Capital Q2 2024 Investor Letter",
      "url": "https://seekingalpha.com/article/4710781-tourlite-capital-q2-2024-investor-letter",
      "time_published": "20240806T070000",
      "authors": [
        "Tourlite Capital Management"
      ],
      "summary": "Tourlite Fund, LP returned 2.7% in Q2 2024 and 8.9% YTD, maintaining a cautious market outlook despite evolving rate cut expectations. The fund highlighted strong performance in its long book, particularly in industrials, and identified key gainers and detractors, including FTAI and OmniAb, while discussing portfolio adjustments and the economic outlook.",
      "banner_image": null,
      "source": "Seeking Alpha",
      "category_within_source": "General",
      "source_domain": "Seeking Alpha",
      "topics": [
        {
          "topic": "financial_markets",
          "relevance_score": "0.938938"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.824948"
        },
        {
          "topic": "economy_monetary",
          "relevance_score": "0.718023"
        },
        {
          "topic": "economy_macro",
          "relevance_score": "0.617235"
        },
        {
          "topic": "finance",
          "relevance_score": "0.600886"
        }
      ],
      "overall_sentiment_score": 0.429602,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "OABI",
          "relevance_score": "0.948526",
          "ticker_sentiment_score": "0.415563",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "OmniAb Announces Publication of Scientific Paper on Heavy Chain-Only Single-Domain Antibody Chicken Platform in the Journal of Immunology",
      "url": "https://www.biospace.com/omniab-announces-publication-of-scientific-paper-on-heavy-chain-only-single-domain-antibody-chicken-platform-in-the-journal-of-immunology",
      "time_published": "20240603T000000",
      "authors": [],
      "summary": "OmniAb, Inc. announced the publication of a peer-reviewed paper in the Journal of Immunology confirming that chickens can be genetically engineered to produce functional heavy chain-only single-domain antibodies. This research underpins OmniAb's novel OmnidAb\u2122 transgenic chicken platform, launched in 2023, which generates fully human and stabilized single-domain antibodies. This development is significant for antibody discovery, offering new avenues for therapeutic approaches and diagnostic applications.",
      "banner_image": "https://www.businesswire.com/news/home/20240603162111/en/",
      "source": "BioSpace",
      "category_within_source": "General",
      "source_domain": "BioSpace",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        }
      ],
      "overall_sentiment_score": 0.447781,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "OABI",
          "relevance_score": "0.954090",
          "ticker_sentiment_score": "0.409048",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Hillstream BioPharma Announces Development of Proprietary Targeted Biologics, Knob Quatrabodies\u2122 (HSB-1940) against PD-1, by combining Quatramers\u2122 with OmniAb\u2019s Picobodies\u2122, via a Collaboration Agreement, against Novel, Unreachable and Un",
      "url": "https://finance.yahoo.com/news/hillstream-biopharma-announces-development-proprietary-134700747.html",
      "time_published": "20221201T134700",
      "authors": [],
      "summary": "Hillstream BioPharma announced the development of proprietary targeted biologics, Knob Quatrabodies\u2122 (HSB-1940) against PD-1, through a collaboration with OmniAb and Minotaur Therapeutics. This initiative combines Hillstream's Quatramers\u2122 with OmniAb\u2019s Picobodies\u2122 to target novel, unreachable, and undruggable epitopes in high-value validated targets, starting with PD-1. The aim is to create next-generation cancer therapeutics with enhanced binding affinity and targeting efficiency for the rapidly growing Immuno-oncology market.",
      "banner_image": null,
      "source": "Yahoo Finance",
      "category_within_source": "General",
      "source_domain": "Yahoo Finance",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.930094"
        }
      ],
      "overall_sentiment_score": 0.332251,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "OABI",
          "relevance_score": "0.951328",
          "ticker_sentiment_score": "0.320170",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    }
  ]
}